Dechra has launched Furosoral, a versatile new product for the initial treatment, or maintenance therapy, of conditions associated with fluid build-up in cats and dogs.
Furosoral contains furosemide as its active ingredient, a diuretic known for its effectiveness in treating fluid build-up and retention. It is suitable for the treatment of hydrothorax, hydropericardium, ascites and oedema, particularly in animals where these conditions are associated with cardiac insufficiency and renal dysfunction.
Furosoral replaces Dechra’s previous diuretic treatment, Frusedale. It is available in both 10mg and 40mg doses and comes in Dechra’s innovative Smart Tab double-divisible format, ensuring that the 10mg and 40mg tablets can easily be split to enable patients to get the precise dose they need. The recommended daily starting dose for cats and dogs is 2.5mg per kg of body weight. Careful weighing is essential to ensure accurate dosing, however the dosage can be doubled initially for severe or particularly resistant cases and adjusted to the lowest clinically effective dose for maintenance therapy should this be required.
Dechra companion animal brand manager, Charlotte Hill, says: “Furosoral offers a flexible treatment solution where dosage can be adjusted, depending on the needs of the patient and the underlying causes, to give vets more options for treating cats and dogs with fluid retention.
“To ensure it is as appealing to pet owners as it is to veterinary professionals, Furosoral is available in our innovative Smart Tab format, giving owners confidence that they are giving their dog or cat the right dosage and aiding compliance, leading to better outcomes for the animal.”
Furosoral 10mg and 40mg tablets are available in blister packs of 100 tablets for quick and easy dispensing. Divided tablets can be stored in the blister pack for up to three days, ensuring no waste.
For further information on Furosoral please contact your local Dechra territory sales manager or visit the Dechra website.
